XML 73 R8.htm IDEA: XBRL DOCUMENT

Organization and Nature of Operations	12 Months Ended
Organization and Nature of Operations	Dec. 31, 2019
Organization and Nature of Operations
Organization and Nature of Operations	Organization and Nature of Operations Supernus Pharmaceuticals, Inc. (the Company) was incorporated in Delaware and commenced operations in 2005. The Company is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets two products: Oxtellar XR for the treatment of epilepsy and Trokendi XR for the prophylaxis of migraine headache and the treatment of epilepsy. The Company is also developing multiple proprietary CNS product candidates to address significant unmet medical needs and market opportunities. The Company launched Oxtellar XR and Trokendi XR for the treatment of epilepsy in 2013, followed by the launch of Trokendi XR for the prophylaxis of migraine headache in adolescents and adults in April 2017. The Company launched Oxtellar XR with an expanded indication to include monotherapy for partial seizures in January 2019.